GlobeNewswire Inc | Nov 22, 2021 07:00AM EST

November 22, 2021

BALA CYNWYD, Pa., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases,today announced that company management will participate in virtual 1x1 investor meetings at the Piper Sandler 33rd Annual Healthcare Conference taking place November 29, 2021 through December 2, 2021.

AboutLarimar Therapeutics

Larimar Therapeutics, Inc.(Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimars lead compound, CTI-1601, is currently being evaluated in a Phase 1 clinical program in theU.S.as a potential treatment for Friedreich's ataxia.Larimaralso plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:Joyce AllaireLifeSci Advisorsjallaire@lifesciadvisors.com(212) 915-2569

Company Contact:Michael CelanoChief Financial Officermcelano@larimartx.com(484) 414-2715